Welcome!

News Feed Item

PharmaPoint: Hepatitis C Virus - United Kingdom Drug Forecast and Market Analysis to 2022

NEW YORK, June 26, 2013 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

PharmaPoint: Hepatitis C Virus - United Kingdom Drug Forecast and Market Analysis to 2022
http://www.reportlinker.com/p01364262/PharmaPoint-Hepatitis-C-Virus---United-Kingdom-Drug-Forecast-and-Market-Analysis-to-2022.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication

PharmaPoint: Hepatitis C Virus - United Kingdom Drug Forecast and Market Analysis to 2022

Summary

GlobalData has released its new Country report, "PharmaPoint: Hepatitis C Virus - United Kingdom Drug Forecast and Market Analysis to 2022". Hepatitis C is a liver infection caused by the hepatitis C virus (HCV) that results in acute or chronic presentation. The disease is often asymptomatic, but infected patients may experience fatigue, joint pain, itchy skin or jaundice. There is no effective vaccine against HCV, so the market is driven by therapeutics. Currently, drug combinations containing pegylated interferon (e.g., Roche's Pegasys and Merck's PegIntron) and ribavirin (e.g., Roche's Copegus and Merck's Rebetol) are used to treat HCV infection. Patients infected with HCV genotype 1 can also have a protease inhibitor added to their combination therapy, such as Merck's Victrelis (boceprevir) or Vertex's Incivek (telaprevir). The entrance of next-generation HCV therapies is expected to fundamentally change the HCV treatment algorithm. GlobalData expects a dramatic shift favoring the uptake of interferon-free regimens due to their more tolerable side-effect profiles and decreased duration of therapy compared with the current standard of care.

The anticipated drivers of growth in the UK market included increased awareness of HCV, the launch of improved HCV regimens, and advocacy for access to next-generation therapies.

Janssen's Incivo is the current market leader in the UK. Incivo was among the first DAA HCV therapies launched in the UK. The regimen had an improved efficacy compared with the previous standard of care for HCV GT1, a combination of peginterferon and ribavirin. GlobalData assumes that Incivo's shorter duration of triple-therapy (i.e., DAA, peginterferon, and ribavirin) compared with Merck's Victrelis enabled it to outcompete Victrelis for market share. Incivo and Victrelis are both associated with adverse events, which has resulted in HCV-infected patients in the UK deciding to forego therapy in order to await the launch of more-tolerable HCV therapies.

Scope

- Overview of the HCV including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
- Detailed information on the key drugs in the UK including product description, safety and efficacy profiles as well as a SWOT analysis.
- Sales forecast for the top drugs in the UK from 2012-2022.
- Analysis of the impact of key events as well the drivers and restraints affecting the UK HCV market.

Reasons to buy

- Understand and capitalize by identifying products that are most likely to ensure a robust return
- Stay ahead of the competition by understanding the changing competitive landscape for HCV
- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
- Make more informed business decisions from insightful and in-depth analysis of drug performance
- Obtain sales forecast for drugs from 2012-2022 in the UK

Table of Contents

1 Table of CContents 4
1.1 List of Tables 7
1.2 List of Figures 9
2 Introduction 10
2.1 Catalyst 10
2.2 Related Reports 10
2.3 Upcoming Related Reports 11
3 Disease Overview 12
3.1 Etiology and Pathophysiology 13
3.1.1 Etiology 13
3.1.2 Pathophysiology 16
3.1.3 Prognosis 17
3.2 Symptoms 17
4 Disease Management 18
4.1 Diagnosis and Referral Overview 18
4.2 Treatment Overview 19
4.3 UK 22
4.3.1 Diagnosis 22
4.3.2 Clinical Practice 23
5 Competitive Assessment 24
5.1 Overview 24
5.2 Strategic Competitor Assessment 24
5.3 Product Profiles – Major Brands 26
5.3.1 Incivek (telaprevir) 26
5.3.2 Victrelis (boceprevir) 31
5.3.3 Pegasys (peginterferon alfa-2a) 36
5.3.4 PegIntron (peginterferon alfa-2b) 41
5.3.5 Copegus, Rebetol, and Generic Ribavirin 45
5.3.6 Therapeutic Class: Interferon 48
6 Opportunity and Unmet Need 49
6.1 Overview 49
6.2 Unmet Needs 50
6.2.1 Unmet Need: Treatment Tolerability 50
6.2.2 Unmet Need: Efficacy 50
6.2.3 Unmet Need: Disease Awareness 51
6.2.4 Unmet Need: Treatment Cost 52
6.2.5 Unmet Need: Shorter Treatment Duration 52
6.2.6 Unmet Need: Simplified Treatment Regimens 53
6.3 Unmet Needs Gap Analysis 54
6.4 Opportunities 55
6.4.1 Opportunity: Pan-genotypic HCV Regimen 55
6.4.2 Opportunity: Treatment of Underrepresented Patient Populations 55
6.4.3 Opportunity: Involvement of Immune System 56
7 Pipeline Assessment 57
7.1 Overview 57
7.2 Promising Drugs in Clinical Development 58
7.2.1 Sofosbuvir and Sofosbuvir/Ledipasvir 60
7.2.2 Simeprevir 70
7.2.3 ABT-450 plus ABT-267 and ABT-333 78
7.2.4 Faldaprevir and Faldaprevir plus BI 207127 85
7.2.5 Daclatasvir and Daclatasvir plus Asunaprevir 93
7.2.6 Other Drug Classes 101
8 Market Outlook 104
8.1 UK 104
8.1.1 Forecast 104
8.1.2 Key Events 109
8.1.3 Drivers and Barriers 109
9 Appendix 112
9.1 Bibliography 112
9.2 Abbreviations 120
9.3 Methodology 121
9.4 Forecasting Methodology 121
9.4.1 Percent Drug-Treated Patients 121
9.4.2 Patient Warehousing 122
9.4.3 Drugs Included in Each Therapeutic Class 122
9.4.4 Launch and Patent Expiry Dates 123
9.4.5 General Pricing Assumptions 124
9.4.6 Individual Drug Assumptions 124
9.4.7 Generic Erosion 126
9.4.8 Selection of Pipeline Agents 126
9.4.9 Pricing of Pipeline Agents 127
9.5 Physicians and Specialists Included in this Study 130
9.6 Survey of Prescribing Physicians 132
9.7 About the Authors 133
9.7.1 Author 133
9.7.2 Global Head of Healthcare 133
9.8 About GlobalData 134
9.9 Contact Us 134
9.10 Disclaimer 134

List of Tables

Table 1: Modes of HCV Transmission 16
Table 2: Symptoms of Acute and Chronic HCV Infection 17
Table 3: HCV Genotypes Present in the 9MM 19
Table 4: General Standard of Care by HCV Genotype 19
Table 5: Treatment Guidelines for HCV by Country 21
Table 6: Most-Prescribed Drugs for HCV by Class in the Global Markets, 2013 21
Table 7: Leading Treatments for HCV, 2012 25
Table 8: Product Profile – Incivek 27
Table 9: Efficacy of Incivek in Treatment-Naïve Patients (ADVANCE Trial) 27
Table 10: Efficacy of Incivek in Treatment-Experienced Patients (REALIZE Trial) 28
Table 11: Common Incivek Adverse Drug Reactions 29
Table 12: Incivek SWOT Analysis, 2012 30
Table 13: Product Profile – Victrelis 31
Table 14: Victrelis Efficacy in Treatment-Naïve Patients (SPRINT-2 Trial) 32
Table 15: Victrelis Efficacy in Treatment-Experienced Patients (RESPOND-2 Trial) 33
Table 16: Victrelis SWOT Analysis, 2012 35
Table 17: Product Profile – Pegasys 37
Table 18: Antiviral Efficacy of Peginterferon alfa-2a Compared with Interferon alfa-2b 38
Table 19: Pegasys SWOT Analysis, 2012 40
Table 20: Product Profile – PegIntron 42
Table 21: Antiviral Efficacy of Peginterferon alfa-2b Compared with Interferon alfa-2b 42
Table 22: PegIntron SWOT Analysis, 2012 44
Table 23: Effect of Addition of Ribavirin to Peginterferon HCV Therapy 46
Table 24: Ribavirin SWOT Analysis, 2012 47
Table 25: Summary of Minor Therapeutic Classes, 2012 48
Table 26: Overall Unmet Needs – Current Level of Attainment 49
Table 27: Clinical Unmet Needs – Gap Analysis, 2012 54
Table 28: HCV – Pipeline, 2012 58
Table 29: Comparison of Therapeutic Classes in Development for HCV, 2012 59
Table 30: Gilead's Sofosbuvir Ongoing Clinical Trials of Interest 61
Table 31: Product Profile – Sofosbuvir 62
Table 32: Sofosbuvir's Most Common Adverse Effects 65
Table 33: Sofosbuvir SWOT Analysis, 2012 69
Table 34: Janssen's Simeprevir Ongoing Clinical Trials of Interest 71
Table 35: Product Profile – Simeprevir 72
Table 36: PILLAR Clinical Trial Results 72
Table 37: Adverse Events Observed in PILLAR Clinical Trial 73
Table 38: Simeprevir SWOT Analysis, 2012 77
Table 39: AbbVie's Combination Therapy Ongoing Clinical Trials of Interest 79
Table 40: Product Profile – AbbVie Combination Therapy 80
Table 41: AVIATOR Clinical Trial Results 80
Table 42: AbbVie Combination Therapy SWOT Analysis, 2012 84
Table 43: Boehringer Ingelheim's Faldaprevir Ongoing Clinical Trials of Interest 86
Table 44: Product Profile – Faldaprevir 87
Table 45: Efficacy of Interferon-Free Faldaprevir Regimen (SOUND-C2 Trial) 87
Table 46: Faldaprevir SWOT Analysis, 2012 92
Table 47: Bristol-Myers Squibb's Daclatasvir Ongoing Clinical Trials of Interest 94
Table 48: Product Profile – Daclatasvir 95
Table 49: Efficacy of Daclatasvir in Treatment-Naïve Patients (COMMAND-1 Trial) 95
Table 50: Daclatasvir and Asunaprevir Quad Therapy Efficacy 96
Table 51: Daclatasvir Triple Therapy Adverse Events 97
Table 52: Daclatasvir SWOT Analysis, 2012 100
Table 53: Comparison of Peginterferon lambda with Peginterferon alfa (EMERGE Trial) 101
Table 54: Efficacy of Alisporivir in Treatment-Naïve HCV GT2/3 Patients (VITAL-1 Trial) 102
Table 55: Sales Forecasts ($m) for HCV in the UK, 2012–2022 107
Table 56: Key Events Impacting Sales for HCV in the UK, 2012 109
Table 57: UK HCV Market – Drivers and Barriers, 2012 109
Table 58: Key Launch Dates 123
Table 59: Key Patent Expiries 123
Table 60: Physicians Surveyed, By Country 132

List of Figures

Figure 1: HCV Genome and Polyprotein Composition 13
Figure 2: HCV Lifecycle Overview 14
Figure 3: Competitive Assessment of Late-Stage Pipeline Agents in HCV, 2012–2022 58
Figure 4: Sales for HCV Therapeutics in the UK by Drug Class, 2012–2022 108

To order this report:
Drug_and_Medication Industry:
PharmaPoint: Hepatitis C Virus - United Kingdom Drug Forecast and Market Analysis to 2022

__________________________
Contact Clare: [email protected]  
US:(339) 368 6001
Intl:+1 339 368 6001

SOURCE Reportlinker

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
There is an ever-growing explosion of new devices that are connected to the Internet using “cloud” solutions. This rapid growth is creating a massive new demand for efficient access to data. And it’s not just about connecting to that data anymore. This new demand is bringing new issues and challenges and it is important for companies to scale for the coming growth. And with that scaling comes the need for greater security, gathering and data analysis, storage, connectivity and, of course, the...
The IoTs will challenge the status quo of how IT and development organizations operate. Or will it? Certainly the fog layer of IoT requires special insights about data ontology, security and transactional integrity. But the developmental challenges are the same: People, Process and Platform. In his session at @ThingsExpo, Craig Sproule, CEO of Metavine, will demonstrate how to move beyond today's coding paradigm and share the must-have mindsets for removing complexity from the development proc...
Redis is not only the fastest database, but it has become the most popular among the new wave of applications running in containers. Redis speeds up just about every data interaction between your users or operational systems. In his session at 18th Cloud Expo, Dave Nielsen, Developer Relations at Redis Labs, will shares the functions and data structures used to solve everyday use cases that are driving Redis' popularity.
Much of the value of DevOps comes from a (renewed) focus on measurement, sharing, and continuous feedback loops. In increasingly complex DevOps workflows and environments, and especially in larger, regulated, or more crystallized organizations, these core concepts become even more critical. In his session at @DevOpsSummit at 18th Cloud Expo, Andi Mann, Chief Technology Advocate at Splunk, will show how, by focusing on 'metrics that matter,' you can provide objective, transparent, and meaningfu...
Many private cloud projects were built to deliver self-service access to development and test resources. While those clouds delivered faster access to resources, they lacked visibility, control and security needed for production deployments. In their session at 18th Cloud Expo, Steve Anderson, Product Manager at BMC Software, and Rick Lefort, Principal Technical Marketing Consultant at BMC Software, will discuss how a cloud designed for production operations not only helps accelerate developer...
Artificial Intelligence has the potential to massively disrupt IoT. In his session at 18th Cloud Expo, AJ Abdallat, CEO of Beyond AI, will discuss what the five main drivers are in Artificial Intelligence that could shape the future of the Internet of Things. AJ Abdallat is CEO of Beyond AI. He has over 20 years of management experience in the fields of artificial intelligence, sensors, instruments, devices and software for telecommunications, life sciences, environmental monitoring, process...
Manufacturers are embracing the Industrial Internet the same way consumers are leveraging Fitbits – to improve overall health and wellness. Both can provide consistent measurement, visibility, and suggest performance improvements customized to help reach goals. Fitbit users can view real-time data and make adjustments to increase their activity. In his session at @ThingsExpo, Mark Bernardo Professional Services Leader, Americas, at GE Digital, will discuss how leveraging the Industrial Interne...
The IETF draft standard for M2M certificates is a security solution specifically designed for the demanding needs of IoT/M2M applications. In his session at @ThingsExpo, Brian Romansky, VP of Strategic Technology at TrustPoint Innovation, will explain how M2M certificates can efficiently enable confidentiality, integrity, and authenticity on highly constrained devices.
Increasing IoT connectivity is forcing enterprises to find elegant solutions to organize and visualize all incoming data from these connected devices with re-configurable dashboard widgets to effectively allow rapid decision-making for everything from immediate actions in tactical situations to strategic analysis and reporting. In his session at 18th Cloud Expo, Shikhir Singh, Senior Developer Relations Manager at Sencha, will discuss how to create HTML5 dashboards that interact with IoT devic...
We're entering the post-smartphone era, where wearable gadgets from watches and fitness bands to glasses and health aids will power the next technological revolution. With mass adoption of wearable devices comes a new data ecosystem that must be protected. Wearables open new pathways that facilitate the tracking, sharing and storing of consumers’ personal health, location and daily activity data. Consumers have some idea of the data these devices capture, but most don’t realize how revealing and...
Struggling to keep up with increasing application demand? Learn how Platform as a Service (PaaS) can streamline application development processes and make resource management easy.
SYS-CON Events announced today that Ericsson has been named “Gold Sponsor” of SYS-CON's @ThingsExpo, which will take place on June 7-9, 2016, at the Javits Center in New York, New York. Ericsson is a world leader in the rapidly changing environment of communications technology – providing equipment, software and services to enable transformation through mobility. Some 40 percent of global mobile traffic runs through networks we have supplied. More than 1 billion subscribers around the world re...
In the world of DevOps there are ‘known good practices’ – aka ‘patterns’ – and ‘known bad practices’ – aka ‘anti-patterns.' Many of these patterns and anti-patterns have been developed from real world experience, especially by the early adopters of DevOps theory; but many are more feasible in theory than in practice, especially for more recent entrants to the DevOps scene. In this power panel at @DevOpsSummit at 18th Cloud Expo, moderated by DevOps Conference Chair Andi Mann, panelists will dis...
We’ve worked with dozens of early adopters across numerous industries and will debunk common misperceptions, which starts with understanding that many of the connected products we’ll use over the next 5 years are already products, they’re just not yet connected. With an IoT product, time-in-market provides much more essential feedback than ever before. Innovation comes from what you do with the data that the connected product provides in order to enhance the customer experience and optimize busi...
The increasing popularity of the Internet of Things necessitates that our physical and cognitive relationship with wearable technology will change rapidly in the near future. This advent means logging has become a thing of the past. Before, it was on us to track our own data, but now that data is automatically available. What does this mean for mHealth and the "connected" body? In her session at @ThingsExpo, Lisa Calkins, CEO and co-founder of Amadeus Consulting, will discuss the impact of wea...